stockrow
Friday 6 November 2026
Export TLPH’s income statement to Excel — free account
Talphera, Inc.
TLPH Healthcare Drug Manufacturers Specialty & Generic
Talphera, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $28,000.00, down 95.7% from fiscal 2023.
- Revenue
- −99.6%
- EPS
- +40.0%
- Free cash flow
- −33.1%
Quarter to June 2026, against a year earlier
1.06
0.05
+4.95%
Follow TLPH
Alert me
Talphera, Inc. (TLPH) P/E ratio
Talphera, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 1.2× (July 2022) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.3× | — |
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
| FY2017 | 0.0× | — |
| FY2016 | 0.0× | — |
| FY2015 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Sep 2025 | 0.0× | — |
| Mar 2025 | 0.0× | — |
| Dec 2023 | 0.0× | — |
| Sep 2023 | 0.0× | — |
| 33 more quarters | Free account |
Against its own ten years
Low 0.0×
High 1.2×
Ten-year median
0.0×
Current reading's percentile
92
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| RMTI Rockwell Medical, Inc. compare | n/m |
| CPIX Cumberland Pharmaceuticals Inc. compare | n/m |
| SCYX SCYNEXIS, Inc. compare | n/m |
| IXHL Incannex Healthcare Inc. compare | n/m |
| CTOR Citius Oncology, Inc. compare | n/m |
| TLPH Talphera, Inc. | n/m |
| ORGO Organogenesis compare | n/m |
| INCR InterCure Ltd. compare | 6.2× |
| ZYBT Zhengye Biotechnology Holding Limited compare | — |
| Drug Manufacturers Specialty & Generic industry median | 20.5× |
| Healthcare sector median | 25.2× |
| Market median | 17.9× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)